Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 13/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vesamicol SCHEMBL4499985 | 0.83 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL571598 | 0.83 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL12648665 | 0.83 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL4499984 | 0.83 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL8984052 | 0.81 | SLC18A3 (0.94) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL13147831 | 0.80 | SLC18A3 (0.66) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL16801372 | 0.75 | SLC18A3 (0.55) | SLC18A3CYP2D6SMN1; SMN2CYP2C9 | |
| SCHEMBL13354836 | 0.75 | SLC18A3 (0.63) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL9980681 | 0.75 | SLC18A3 (0.55) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL4050011 | 0.74 | HDAC1 (0.45) | CYP2D6SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | SLC18A3 248/4885CYP2D6 548/4885TSHR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.